Here are the 8-K filings from VitaSpring Biomedical Co (VSBC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow VSBC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VSBC filings page.
VITASPRING BIOMEDICAL CO., LTD. (VSBC) reports a leadership transition effective late on September 7, 2026. At 11:58 p.m. Pacific Time, Dr. Ssu‑Chuan Lai resigned as Chairperson of the Board, Chief Executive Officer, President, Chief Financial Officer, Secretary, and as a director. The company states that Dr. Lai’s resignation was not the result of any disagreement relating to operations, policies, or practices, and her resignation letter is included as an exhibit.
Immediately before this, Dr. Lai, as the sole director, elected Shao‑Hsiang Shih as a director at 11:56 p.m. and designated him Chairman at 11:57 p.m., and appointed Jing‑Zhou Chen as Chief Executive Officer, President, Chief Financial Officer, and Secretary at 11:57 p.m. Mr. Chen is designated as principal executive, financial, and accounting officer. Both Mr. Chen and Mr. Shih currently receive no compensation for their roles unless later determined by the board, have no disclosed related-party transactions or family relationships with existing officers or directors, and are entitled to indemnification and advancement of expenses to the fullest extent permitted by Nevada law and the company’s governing documents.